Inclusion Criteria:

- Patients with histologically/ cytologically documented or radiographically diagnosed
unresectable HCC who are candidates for systemic therapy and for whom a decision to
treat with sorafenib has been made. Radiographic diagnosis needs typical findings of
HCC by radiographic method i.e. on multi-dimensional dynamic CT, CT hepatic
arteriography (CTHA)/CT arterial portography (CTAP) or MRI;

- Patients receive the first dose of sorafenib no later than 1 week (<=7days) after the
3rd TACE procedure

- Patients did not receive other prior systemic treatment by using target therapy

- Patients must sign the informed consent form;

- Patients must have a life expectancy of at least 3 months;

- The physician must be willing to complete and submit all CRFs;

- The physician must be willing to submit to a site audit with verification of source
documents and validation of data reported;

Exclusion Criteria:

- The first dose of sorafenib 7 days after the 3nd TACE procedure

- Exclusion criteria must follow the approved local product information